12/19
09:22 am
lexx
Lexaria's Registered GLP-1 Study #4 Begins Dosing [Yahoo! Finance]
Medium
Report
Lexaria's Registered GLP-1 Study #4 Begins Dosing [Yahoo! Finance]
12/19
09:05 am
lexx
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Medium
Report
Lexaria's Registered GLP-1 Study #4 Begins Dosing
12/18
09:45 am
lexx
Lexaria Forms New Scientific Advisory Board [Yahoo! Finance]
Low
Report
Lexaria Forms New Scientific Advisory Board [Yahoo! Finance]
12/18
09:25 am
lexx
Lexaria Forms New Scientific Advisory Board
Low
Report
Lexaria Forms New Scientific Advisory Board
12/17
09:10 am
lexx
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Medium
Report
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
12/9
09:34 am
lexx
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 [Yahoo! Finance]
Medium
Report
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 [Yahoo! Finance]
12/9
09:10 am
lexx
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Low
Report
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
12/2
08:06 am
lexx
Lexaria Bioscience Corp. (NASDAQ: LEXX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Lexaria Bioscience Corp. (NASDAQ: LEXX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/28
06:20 am
lexx
Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Low
Report
Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
11/26
09:40 am
lexx
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs [Yahoo! Finance]
Medium
Report
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs [Yahoo! Finance]
11/26
09:20 am
lexx
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Medium
Report
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
11/25
09:20 am
lexx
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled [Yahoo! Finance]
Medium
Report
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled [Yahoo! Finance]
11/25
09:00 am
lexx
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Medium
Report
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
11/25
08:05 am
lexx
Lexaria Bioscience Corp. (NASDAQ: LEXX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Lexaria Bioscience Corp. (NASDAQ: LEXX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/20
09:28 am
lexx
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study [Yahoo! Finance]
Neutral
Report
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study [Yahoo! Finance]
11/20
09:05 am
lexx
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
Low
Report
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
11/14
09:32 am
lexx
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study [Yahoo! Finance]
Medium
Report
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study [Yahoo! Finance]
11/14
09:10 am
lexx
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
High
Report
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
11/13
09:20 am
lexx
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Medium
Report
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
11/7
09:38 am
lexx
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments [Yahoo! Finance]
Medium
Report
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments [Yahoo! Finance]
11/7
09:15 am
lexx
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Medium
Report
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
10/24
09:27 am
lexx
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study [Yahoo! Finance]
Low
Report
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study [Yahoo! Finance]
10/24
09:10 am
lexx
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Low
Report
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
10/22
09:30 am
lexx
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study [Yahoo! Finance]
Low
Report
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study [Yahoo! Finance]
10/22
09:20 am
lexx
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Medium
Report
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study